



**GORE® SYNECOR**  
Intraperitoneal Biomaterial

# MATERIAL INNOVATION FOR PERMANENT STRENGTH



*Together, improving life*



## Innovative materials for specialized solutions

Gore makes a relentless commitment to improving lives through deliberate product innovation

- We have a comprehensive portfolio of biomaterials intended to meet the needs of abdominal wall reconstruction and hernia repair.
- Each biomaterial is specifically designed with the patient and surgeon in mind.
- Our biomaterials have a history of bringing sustainable clinical results to patients.

Consistent quality offers confidence to providers, surgeons and patients

GORE® SYNECOR Intraperitoneal Biomaterial helps deliver the quality outcomes patients need.

- Repair with the GORE® SYNECOR Intraperitoneal Biomaterial may result in low rates of procedural interventions for surgical site occurrences (SSOPI).<sup>1,2</sup>

May improve the economics of patient care.

- Potentially lower total cost of treatment\* versus lightweight and mid-weight meshes, which have clinical literature case studies demonstrating failure due to inadequate strength in ventral and incisional hernia repairs.<sup>3-5</sup>

\* which includes reduced risk of hospitalization, chronic pain and reoperation.



Designed for ease of use during minimally invasive (laparoscopic, robotic) and open surgical procedures<sup>6</sup>

- Material is flexible and conformable
- Material memory for easy unrolling, handling and optimal placement
- Absorbs fluids (i.e., blood)
- No pre-soaking needed, but may be dipped in sterile saline to facilitate handling



GORE® SYNECOR Intraperitoneal Biomaterial is available in sizes ranging from 12 cm circle to 20 cm x 30 cm rectangle.

# Bringing the latest innovations to hernia repair

GORE® SYNECOR Intraperitoneal Biomaterial is a tri-layer hybrid solution designed for durable repair in complex patients (VHWG 2) to facilitate healing.<sup>1,7</sup>

## GORE 3D PGA:TMC\* Web Scaffold


Provides rapid vascularization<sup>8</sup> and tissue ingrowth<sup>9</sup> designed to facilitate healing.

## PTFE

Latest generation PTFE fiber is designed for permanent strength.<sup>6</sup> Strong and compliant: The PTFE knit is designed with a fiber diameter similar to lightweight mesh, but with the strength of heavyweight mesh.<sup>6,10,11</sup>

## Non-porous PGA:TMC film


Provides intra-abdominal protection, minimizing risk of visceral attachment.<sup>1,9,12,13</sup>



\* Poly (glycolide:trimethylene carbonate) copolymer (PGA:TMC).

# Facilitates the natural healing process with tri-layer biomaterial technology

The effect of pore size<sup>14,15</sup>




As pioneers of the first mid-term bioabsorbable mesh with a targeted absorption period of six to seven months,<sup>13</sup> we are persistent in the pursuit of perfecting material solutions, so surgeons have more options when assessing the risk for complications and supporting complex cases.

Built upon tri-layer technology, GORE® SYNECOR Intraperitoneal Biomaterial is designed to provide a strong repair with minimal permanent material.

\* Poly (glycolide:trimethylene carbonate) copolymer (PGA:TMC).

# Rapid vascularization and tissue ingrowth


Vascularity within GORE 3D PGA:TMC Web Scaffold increases over time<sup>16</sup>





Parietal layer: GORE 3D PGA:TMC\* Web Scaffold fosters cellular infiltration and rapid vascularization which may aid in the overall treatability of the device to mitigate the need for removal if postoperative infection were to occur.<sup>1,2,8,9</sup>

- Enhances tissue response: Designed to promote rapid cell integration and vascularization.<sup>8,9</sup>
- Designed to break down primarily by hydrolysis and provide tissue uniformity and consistency.
- Within seven days: Tissue shows vascularity.<sup>8</sup>
- At 30 days: Tissue ingrowth.<sup>9</sup>
  - Tissue ingrowth is present throughout the GORE 3D PGA:TMC\* Web Scaffold with various densities around the knit fibers and within the scaffold.<sup>9</sup>
  - Ingrowth is vascularized, organized and fills the macropores.<sup>9</sup>
- At 180 days: Tissue generation.<sup>13</sup>
  - GORE 3D PGA:TMC Web Scaffold is absorbed, leaving organized fibrous tissue ingrowth.<sup>13</sup>
  - Minimal fibrous tissue encapsulation of the PTFE knit.<sup>13</sup>

Material replaced by patient's own tissue<sup>17</sup>



† Cells and blood vessels make up remaining volume. GORE® BIO-A® Hernia Plug.



Arrows indicate area where blood vessels are penetrating through the PTFE knit at seven days post-implantation.<sup>8</sup>

\* Poly (glycolide:trimethylene carbonate) copolymer (PGA:TMC).

# Latest generation PTFE fiber is designed for permanent strength<sup>6</sup>

Mid-layer: Macroporous knit of dense, monofilament PTFE fiber


The treatment of ventral hernias with prosthetic devices has reduced recurrence rates but has led to questions concerning infection. Open hernia repair has been associated with infection rates from 3 percent to 18 percent.<sup>18</sup> Laparoscopic ventral hernia repair has been associated with a lower incidence of infection.<sup>18</sup>

The dense monofilament PTFE fiber in GORE® SYNECOR Intraperitoneal Biomaterial may reduce the risk of bacterial adherence, which may result in low rates of surgical site infections (SSI).<sup>1,2,19</sup>


## Optimal porosity

The PTFE knit of GORE® SYNECOR Intraperitoneal Biomaterial has a large pore size (1–3 mm). As demonstrated in animal models, large pore sizes have been shown to improve the mechanical strength of tissue ingrowth<sup>20</sup> and reduce scar plate formation.<sup>21</sup>


The large pore size of the PTFE knit mesh promotes tissue integrity with minimal chronic inflammation, and along with the conformable low-profile design may result in low rates of patient reports of chronic pain at the repair site.<sup>1,2</sup>



GORE® SYNECOR Biomaterial:  
Macroporous knit of dense monofilament PTFE fiber



Polypropylene knit



Unique tri-layer hybrid device:  
GORE® SYNECOR Intraperitoneal Biomaterial


# Provides strength for large defects and higher BMIs

## Strong and compliant

PTFE knit is designed with a fiber diameter similar to lightweight mesh, but with the strength of heavyweight mesh.<sup>6,10,11</sup>

## Permanent strength

Burst strength is > 500 N. This provides strength for large defects and higher BMIs at almost two times the strength requirement for bridging ventral hernia repairs.<sup>11,22,23</sup>



## Durable strength of the material helps to support robust healing

- May lower risk of recurrence versus lightweight and midweight meshes, which may have inadequate strength in complex patients (VHWG 2).<sup>3-5,10,11</sup>

BD is a trademark of Becton, Dickinson and Company.

MEDTRONIC, PARIETEX and SYMBOTEX are trademarks of Medtronic, Inc.



# PTFE fiber

may reduce the risk of bacterial adherence, which may result in low rates of surgical site infections (SSI)<sup>1,2,19</sup>

Bacterial adherence was examined among various materials, including the PTFE knit of GORE® SYNECOR Intraperitoneal Biomaterial, various polypropylene knits and a polyvinylidene fluoride/polypropylene construct.

The materials were incubated in *Staphylococcus aureus* overnight, rinsed and subjected to staining and analysis through confocal microscopy.

This allowed for analysis of where bacteria attached.


Overall, bacteria localize to the knots and fiber surfaces of all test articles examined in this study.

Confocal images suggest that no bacteria are located within the PTFE knit fibers and overall fewer bacteria are located on PTFE knit fibers than other materials.

---


**PTFE knit had the least bacterial adherence on the surface when compared with other competitive polypropylene knits.<sup>19</sup>**

---




Gore's latest-generation PTFE macroporous knit.


PTFE knit (10×)




Polypropylene knit (10×)



Lightweight polypropylene knit (10×)



Polyvinylidene/Polypropylene knit (10×)



*Staphylococcus aureus* stains green; red represents the fiber materials as reflected light.


# Designed to provide predictable performance

## Minimal contraction

Animal studies show GORE® SYNECOR Intraoperative Biomaterial has minimal contraction at 30 and 180 days.<sup>9,13</sup>

Due to the normal healing process of the wound contracting, all biomaterials, including polypropylene, polyester, and PTFE experience some degree of contraction after implantation.<sup>24</sup> This is due to the natural wound healing activity associated with myofibroblasts and not the mesh itself “shrinking” or contracting.<sup>25</sup>

Device	Days-in-life	% change in area
GORE® SYNECOR Intraoperative Biomaterial	31	-5.1%
	180	-6.6%



GORE® SYNECOR Intraoperative Biomaterial: 18-months post-implantation view showing robust collagen formation and vascularization.


Image courtesy of R. Opreanu, M.D.

# Minimizing risk of visceral attachment

Protection from abdominal adhesion formation may lower the risk of postoperative complications and reoperation.

Visceral layer: Non-porous PGA:TMC film provides intra-abdominal protection, minimizing risk of visceral attachment.<sup>1,9,12,13</sup>

- PGA:TMC film: A non-porous film, minimizes visceral attachment to the material.
- Designed to limit cellular penetration.
- Film provides a uniform surface while the neoperitoneum is forming.
- PGA:TMC film absorbs in six to seven months.<sup>9,13</sup>
- Animal studies have shown no mid-substance adhesions to the material at both 30 and 180 days.<sup>9,13</sup>
- No complications due to adhesions observed clinically at 12 months.<sup>1</sup>



The non-porous film is designed to be durable and support ease of use of the device during typical surgical manipulation.\* The durable film withstands scraping by tackers.†

Postoperative observation of GORE® SYNECOR Intra-peritoneal Biomaterial: 9 ½ weeks post implantation



Image courtesy of C. R. Doerhoff, M.D.

\* Such as trimming, insertion through a trocar, positioning, handling with graspers and contact with tackers.

† As tested under wet conditions using a handheld tacker device in a benchtop model.

BD and VENTRALIGHT are trademarks of Becton, Dickinson and Company.

MEDTRONIC, PARIETEX and SYMBOTEX are trademarks of Medtronic, Inc.

# No Gore biomaterials are human, animal or tissue-derived

These biomaterials eliminate the risk of disease transmission by tissue-derived products, residual cellular debris or conflict with religious beliefs/cultural practices.<sup>27</sup>

## Sustainability

**Visit: Gore's commitment to sustainability**

**<https://gmd.cm/VBS-Sustainability>**

## Imaging

The GORE® SYNECOR Intraperitoneal Biomaterial should be visible in CT and MRI images. Because of the density differences between PTFE and the rest of the body, high resolution imaging techniques, such as CT and MRI, will reveal PTFE, both immediately following implant and after ingrowth. The material will not be damaged nor interfere with the MRI other than by being visible.

# GORE<sup>®</sup> SYNECOR Intraperitoneal Biomaterial helps deliver the quality outcomes patients need

Linn et al. Study overview<sup>1</sup>

## Clinical outcomes

Long-term results for intraperitoneal biomaterial repair of ventral hernias in a real-world, retrospective, multicenter study.<sup>1</sup>

## Aim

To analyze device safety and clinical outcomes of ventral hernia repair with a hybrid biomaterial.

## Materials and methods

Retrospective, multicenter, case review analyzed device/procedure endpoints and patient-reported outcomes in patients treated for hernia repair  $\geq 1$  year from study enrollment.

## DATA SUMMARY

Long-term follow-up:

**33 months median**


Range: 14–53 months

- Patients: **459**
- Intraperitoneal placement: **75.6%**
- **57.3%** of all repairs were bridged
- Laparoscopic or robotic approach: **95.4%**



## QUALITY OUTCOMES

- Hernia recurrence:
  - **0.9%** clinically confirmed hernia recurrence (4/459 patients, median 33 months)
- Mesh removal:
  - **0.2%** (not due to infection)
- Reoperation rate:
  - **2.4%** (30 days)
- Surgical site infection (SSI): **2.2%** (12 months)
- Surgical site occurrence requiring procedural intervention (SSOPI): **2.6%** (24 months)
- Complications\*: **0%** (12 months)



## PATIENT CHARACTERISTICS

- Mean body mass index (BMI): **> 33kg/m<sup>2</sup>**
  - Obese: **63%**
- Tobacco users:
  - Current users: **19%**
  - Former users: **32%**
- Diabetes mellitus: **20%**
- Ventral hernia working group (VHWG) classification
  - Grade 1: **23%**
  - Grade 2: **77%**



Linn JG, Mallico EJ, Doerhoff CR, Grantham DW, Washington RG Jr. Evaluation of long-term performance of an intraperitoneal biomaterial in the treatment of ventral hernias. *Surgical Endoscopy* 2023;37:3455-3462. <https://link.springer.com/article/10.1007/s00464-022-09803-9>

\* due to adhesions, seroma, fistula, bowel perforation or pain

# Innovative materials for specialized solutions

## Competitor reference chart

Depending on patient selection criteria, clinicians may utilize GORE® SYNECOR Intraoperative Biomaterial in place of the following products:

Manufacturer	Product name	Composite mesh	Absorbable mesh	Permanent mesh	Reinforced biologic mesh
Becton, Dickinson and Company	BD® VENTRALIGHT ST Mesh	●			
Becton, Dickinson and Company	BD® PHASIX ST Mesh		●		
FEG Textiltechnik mbH	FEG TEXTILTECHNIK DYNAMESH®-IPOM			●	
Medtronic, Inc.	MEDTRONIC PARIETENE DS Composite Mesh	●			
Medtronic, Inc.	MEDTRONIC PARIETEX Optimized Composite (PCOx) Mesh	●			
Medtronic, Inc.	MEDTRONIC SYMBOTEX Composite Mesh	●			
TELA Bio, Inc.	TELA BIO® OVIETEX® LPR Reinforced Tissue Matrix				●

## Sizing

Catalogue number	Description
GKFC12E	12 cm diameter circle
GKJV1015E	10 cm × 15 cm oval
GKJV1520E	15 cm × 20 cm oval
GKFR2025E	20 cm × 25 cm rectangle
GKFR2030E	20 cm × 30 cm rectangle



BD, PHASIX and VENTRALIGHT are trademarks of Becton, Dickinson and Company.

FEG TEXTILTECHNIK and DYNAMESH are trademarks of FEG Textiltechnik mbH.

MEDTRONIC, PARIETEX, PARIETENE and SYMBOTEX are trademarks of Medtronic, Inc.

TELA BIO and OVIETEX are trademarks of TELA Bio, Inc.

## References

1. Linn JG, Mallico EJ, Doerhoff CR, Grantham DW, Washington RG Jr. Evaluation of long-term performance of an intraperitoneal biomaterial in the treatment of ventral hernias. *Surgical Endoscopy* 2023;37:3455-3462.
2. W. L. Gore & Associates, Inc. *Clinical Evaluation Report for GORE® SYNECOR Intraperitoneal Biomaterial*. Flagstaff, AZ: W. L. Gore & Associates, Inc; 2022. [Clinical Evaluation Report – CER]. MD146932. Rev 5.
3. Petro CC, Nahabet EH, Criss CN, et al. Central failures of lightweight monofilament polyester mesh causing hernia recurrence: a cautionary note. *Hernia* 2015;19(1):155-159.
4. Cobb WS, Warren JA, Ewing JA, Burnikel A, Merchant M, Carbonell AM. Open retromuscular mesh repair of complex incisional hernia: predictors of wound events and recurrence. *Journal of the American College of Surgeons* 2015;220(4):606-613.
5. Warren JA, McGrath SP, Hale AL, Ewing JA, Carbonell AM 2<sup>nd</sup>, Cobb WS 4<sup>th</sup>. Patterns of recurrence and mechanisms of failure after open ventral hernia repair with mesh. *American Surgeon* 2017;83(11):1275-1282.
6. W. L. Gore & Associates, Inc. *GORE SYNECOR Intraperitoneal Biomaterial Design Control (DC) Matrix*. Flagstaff, AZ: W. L. Gore & Associates, Inc; 2023. [Design Control Matrix – DC Matrix]. MD184278. Rev 2.
7. Ventral Hernia Working Group, Breuing K, Butler CE, et al. Incisional ventral hernias: review of the literature and recommendations regarding the grading and technique of repair. *Surgery* 2010;148(3):544-558.
8. Crawford N. *Assessment of Vascularity via Micro CT in Various Patch Devices*. Flagstaff, AZ: W. L. Gore & Associates, Inc; 2016. [Final study report]. 2344TL.
9. Berman A. *Evaluation of Plexus with film and ETHICON PHYSIOMESH® in a 30-day rabbit intraperitoneal model*. Flagstaff, AZ: W. L. Gore & Associates, Inc; 2015. [Study protocol]. 2335SC.
10. W. L. Gore & Associates, Inc. *Plexus Knit PQ Validation Report*. Flagstaff, AZ: W. L. Gore & Associates, Inc; 2022. [Validation Report]. MD145325. Rev 5.
11. Olson TB. *Competitive Hernia Device Strength Evaluation*. Flagstaff, AZ: W. L. Gore & Associates, Inc; 2016. [Work plan]. WP108484.
12. Matthews BD. Absorbable and nonabsorbable barriers on prosthetic biomaterials for adhesion prevention after intraperitoneal placement of mesh. *International Surgery* 2005;90(3)Supplement:S30-S34.
13. Berman A. *Evaluation of Plexus with film and ETHICON PHYSIOMESH® in a 180-day rabbit intraperitoneal model*. Flagstaff, AZ: W.L. Gore & Associates, Inc; 2015. [Study protocol]. 2337SC.
14. Sharkawy AA, Klitzman B, Truskey GA, Reichert WM. Engineering the tissue which encapsulates subcutaneous implants. II. Plasma-tissue exchange properties. *Journal of Biomedical Materials Research* 1998;40(4):586-597.
15. Holt DJ, Grainger DW. Host response to biomaterials. In: Hollinger JO, ed. *An Introduction to Biomaterials*. 2nd ed. Boca Raton, FL: CRC Press; 2012;6:91-118.
16. Berman A. *A Rabbit Model for the Biomechanical and Histological Assessment of Suture Line Wound Healing*. Flagstaff, AZ: W. L. Gore & Associates, Inc; 2008. [Study protocol]. 1978SC.
17. Morales-Conde S, Flores M, Fernández V, Morales-Méndez S. Bioabsorbable vs polypropylene plug for the “Mesh and Plug” inguinal hernia repair. Poster presented at the 9th Annual Meeting of the American Hernia Society. February 9-12, 2005; San Diego, CA.
18. LeBlanc KA, Heniford BT, Voeller GR. Innovations in ventral hernia repair. Materials and techniques to reduce MRSA and other infections. *Contemporary Surgery* 2006;62(4)Supplement:1-8.
19. Clinger L. *PTFE Knit Microbial Placement*. Flagstaff, AZ; W. L. Gore & Associates, Inc; 2018. [Work plan]. WP110158.
20. Lake SP, Ray S, Zihni AM, Thompson DM Jr, Gluckstein J, Deeken CR. Pore size and pore shape—but not mesh density—alter the mechanical strength of tissue ingrowth and host tissue response to synthetic mesh materials in a porcine model of ventral hernia repair. *Journal of the Mechanical Behavior of Biomedical Materials* 2015; 42:186-197.
21. Klinge U, Klosterhalfen B, Birkenhauer V, Junge K, Conze J, Schumpelick V. Impact of polymer pore size on the interface scar formation in a rat model. *Journal of Surgical Research* 2002;103(2):208-214.
22. Zhu LM, Schuster P, Klinge U. Mesh implants: an overview of crucial mesh parameters. *World Journal of Gastrointestinal Surgery* 2015;7(10):226-236.
23. Klinge U, Klosterhalfen B, Conze J, et al. Modified mesh for hernia repair that is adapted to the physiology of the abdominal wall. *European Journal of Surgery* 1998;164(12):951-960.
24. Socea B, Socea LI, Bratu OG, et al. Recurrence rates and mesh shrinkage after polypropylene vs. polyester mesh hernia repair in complicated hernias. *Materiale Plastice* 2018;55(1):79-81.
25. Klosterhalfen B, Junge K, Klinge U. The lightweight and large porous mesh concept for hernia repair. *Expert Reviews in Medical Devices* 2005;2(1):103-117.
26. Klitchko M. *SYNECOR IP - Comparison of Film Strength to Competitive Intraperitoneal Hernia Meshes*. Flagstaff, AZ: W. L. Gore & Associates, Inc; 2019. [Work plan]. WP110536.
27. Jenkins ED, Yip M, Melman L, Frisella MM, Matthews BD. Informed consent: cultural and religious issues associated with the use of allogeneic and xenogeneic mesh products. *Journal of the American College of Surgeons* 2010;210(4):402-410.

This product brochure is intended for surgeons and health care providers only.

 Consult Instructions  
for Use  
[eifu.goremedical.com](http://eifu.goremedical.com)

Refer to *Instructions for Use* at [eifu.goremedical.com](http://eifu.goremedical.com) for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx only

Products listed may not be available in all markets.

BD, PHASIX and VENTRALIGHT are trademarks of Becton, Dickinson and Company.  
FEG TEXTILTECHNIK and DYNAMESH are trademarks of FEG Textiltechnik mbH.  
MEDTRONIC, PARIETEX, PARIETENE and SYMBOTEX are trademarks of Medtronic, Inc.  
TELA BIO and OVITEX are trademarks of TELA Bio, Inc.

GORE, *Together, improving life*, BIO-A, SYNECOR and designs are trademarks of W. L. Gore & Associates.  
© 2023 W. L. Gore & Associates GmbH 231241769-EN JANUARY 2024

---

**W. L. Gore & Associates, Inc.**  
[goremedical.com](http://goremedical.com)

**Asia Pacific** +65 6733 2882 **Australia/New Zealand** 1800 680 424 **Europe** 00800 6334 4673  
**United States** Flagstaff, AZ 86003 800 437 8181 928 779 2771

